estradiol-benzoate--progesterone-drug-combination and Hypothyroidism

Three studies assessed the effect of thyroid status on regulation of plasma IGF-I in cattle. First, four Angus-Hereford steers (av wt 345 kg) were fed 4 mg/d propylthiouracil daily for 35 d. With continued feeding of PTU steers were sequentially injected with thyroxine (T4, 5 mg/d, IM for 5 d) followed by triiodothyronine (T3, 2 mg/d, IM for 5 d). An injection of bovine pituitary growth hormone (GH, 0.1 mg/kg, IM) was given to each steer on day 35 of PTU, day 5 of T4 and again on day 5 of T3. PTU alone increased plasma thyroid stimulating hormone (TSH), decreased plasma T4 and T3 but had no influence on IGF-I. T3, but not T4, lowered plasma TSH, IGF-I and the IGF-I response to GH (P < .05). Next, twelve bull calves (av wht 167 kg) were divided equally into two groups. A control group was injected daily for five d with buffered saline; the experimental group was concurrently treated with T3 (5 mg/d, sc) for five d. Beginning the sixth day, all calves were injected with GH (0.1 mg/kg, IM daily) for three d with the respective buffer or T3 treatments continuing. Plasma IGF-I was depressed 29% by T3. The incremental area under the three-d response curve was less (P < .03) in T3 cattle. A growth trial was conducted in which twenty-four Angus x Hereford steers were injected daily with T3 (2 mg/kg, bi-daily x 56 d) or implanted with Synovex-S (S) in a 2 x 2 factorial arrangement. Synovex increased empty body protein gain (EBPG) and plasma IGF-I 15.5 and 27.9% (P < .01), respectively; T3 decreased EBPG and plasma IGF-I 13.9 and 15.1% (P < .07), respectively, in steers which maintained suppression in plasma TSH. The data support the conclusion that elevated T3 decreases plasma IGF-I, in part, through a diminished GH-responsiveness and anabolic treatments such as S can reverse the effects of excess T3.

Topics: Animals; Cattle; Cattle Diseases; Drug Combinations; Drug Interactions; Estradiol; Gene Expression Regulation; Growth Hormone; Hypothyroidism; Insulin-Like Growth Factor I; Least-Squares Analysis; Male; Multivariate Analysis; Pituitary Gland; Progesterone; Propylthiouracil; Protein Biosynthesis; Random Allocation; Thyroid Gland; Thyrotropin; Thyroxine; Time Factors; Triiodothyronine

The effects of propylthiouracil (PTU)-induced thyroid hormone imbalance on GH, TSH and IGF-I status in cattle were examined. In the first study, four crossbred steers (avg wt 350 kg) were fed a diet dressed with PTU (0, 1, 2 or 4 mg/kg/d BW) in a Latin square design with four 35-d periods. On day 29 in each period, steers were challenged with an intrajugular bolus of thyrotropin releasing hormone (TRH, 1.0 microgram/kg). Blood samples were obtained to assess the change in plasma GH and TSH as affected by PTU. Plasma IGF-I was measured from blood samples obtained before and after (every 6 hr for 24 hr) intramuscular injection of bovine GH (0.1 mg/kg, day 31). Doses of 1 and 2 mg/kg PTU increased plasma T4 (P < .01). At 4 mg/kg, PTU depressed T4 concentrations to 30% of control (P < .01). Plasma T3 linearly decreased with increasing doses of PTU (P < .01). Plasma TSH increased when PTU was fed at 4 mg/kg (P < .05) while the TSH response to TRH declined with increasing PTU (P < .02). Neither basal nor TRH-stimulated plasma concentration of GH was affected by PTU; the IGF-I response to GH tended to increase at the 1 and 2 mg/kg PTU (P < .01). In a second study 24 crossbred steers were fed PTU (1.5 mg/kg) for 119 d in a 2 x 2 factorial design with implantation of the steroid growth effector, Synovex-S (200 mg progesterone + 20 mg estradiol), as the other main effect. Basal plasma GH and IGF-I were not affected by PTU treatment. Synovex increased plasma concentration (P < .01) of IGF-I without an effect on plasma GH. The data suggest that mild changes in thyroid status associated with PTU affects regulation of T3, T4 and TSH more than GH or IGF-I in steers.

Topics: Animals; Cattle; Cattle Diseases; Drug Combinations; Estradiol; Growth Hormone; Hypothyroidism; Insulin-Like Growth Factor I; Male; Progesterone; Propylthiouracil; Thyroid Hormones; Thyrotropin; Thyrotropin-Releasing Hormone